Abstract: FR-PO0652
ANCA-Associated Glomerulonephritis: The Qatar Experience
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - ANCA/FSGS
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Aqeel, Faten, Hamad Medical Corporation, Doha, Qatar
- Fituri, Omar, Hamad Medical Corporation, Doha, Qatar
- Nauman, Awais, Hamad Medical Corporation, Doha, Qatar
- Alkadi, Mohamad M., Hamad Medical Corporation, Doha, Qatar
- Eltayeb, Fatima Babiker ahmed, Hamad Medical Corporation, Doha, Qatar
- Hamid, Eiman Mohamed, Hamad Medical Corporation, Doha, Qatar
- Abuhelaiqa, Essa, Hamad Medical Corporation, Doha, Qatar
- Murshed, Khaled, Hamad Medical Corporation, Doha, Qatar
- Asim, Muhammad, Hamad Medical Corporation, Doha, Qatar
- Al-Malki, Hassan A., Hamad Medical Corporation, Doha, Qatar
Background
Data on ANCA-associated glomerulonephritis from the Gulf region are scarce. This study describes the clinical characteristics and outcomes of ANCA-GN in Qatar.
Methods
We retrospectively studied adults with ANCA-associated GN diagnosed at Hamad Medical Corporation from 2015–2025. Primary outcomes were ESKD and mortality; secondary outcomes included kidney function, proteinuria, relapse, and infections. Statistical analyses were performed as appropriate.
Results
Twenty-eight patients were followed for a median of 16 months. Median age was 49 years; 71% were male and 54% South Asian. Seasonal peaks occurred in winter (43%) and summer (32%). Pulmonary involvement was present in 57%. PR3-ANCA was positive in 43%, MPO-ANCA in 36%, and atypical ANCA in 18%. One patient was quadruple positive (MPO+PR3+ANA+GBM). Five (18%) patients had relapsing disease, and two (7%) had refractory disease. Mixed (50%) and crescentic (25%) histologic classes predominated. Despite 61% having low-to-moderate AKRiS, 39% progressed to ESKD, and 14% died. Only 54% received maintenance therapy, and most deaths were infection-related. Lack of hematuria resolution, failure of early proteinuria reduction, and absence of maintenance therapy were associated with ESKD (p < 0.05).
Conclusion
ANCA-associated glomerulonephritis in Qatar is associated with high ESKD rates, highlighting opportunities for improved monitoring, timely treatment, and standardized care pathways.
| Table 1: Renal Outcomes | |
| Serum creatinine at the time of diagnosis, mg/dL | 3.94 [2.17–5.84] |
| Nadir serum creatinine at 1-3 months, mg/dL | 1.66 [1.04–2.85] |
| Nadir serum creatinine at 6-12 months, mg/dL | 1.36 [1.00–1.89] |
| Urine protein to creatinine ratio at the time of diagnosis, mg/g | 2247.5 [1158.5–3486.3] |
| Nadir urine protein to creatinine ratio at 1-3 months, mg/g | 1283 [698.5–2260] |
| Nadir urine protein to creatinine ratio at 6-12 months, mg/g | 459 [168–1057.3] |
| Presence of microscopic hematuria at the time of diagnosis | 28 (100) |
| Resolution of microscopic hematuria at the time of last follow-up | 16 (57) |
Data are presented as n (%) or median [IQR]